Take the Pain Out of Pain Management With Ethiqa XR

3 Days of Pain Relief with 1 Pharmaceutical-Grade Dose.

New Ethiqa XR from Fidelis Pharmaceuticals is the first and only pharmaceutical grade extended-release buprenorphine proven effective in reducing pain for lab mice and rats up to 72 hours after administration of just one injection. See efficacy and safety.

Pure Pain Relief

Now Available though MWI Animal Health and Covetrus
Ethiqa XR will offer:

  • Simple ordering
  • Low-viscosity formula
  • Easy administration

An Ethical Imperative
Effective pain management for laboratory animals is an essential need in today’s research. Learn more about industry association guidelines.

  • Fidelis Pharmaceuticals, the U.S.-based manufacturer of Ethiqa XR, is deeply committed to improving animal welfare with innovative new solutions for reducing discomfort in lab animals.
  • The Fidelis leadership team supports the foremost veterinary, laboratory research, and human healthcare industry associations and initiatives, including:

Want to learn more? Register for a webinar or to stay up-to-date on product availability.


Sign-Up for a webinar today!

Important Safety Information


Abuse Potential

This formulation contains buprenorphine, a high-concentration (1.3 mg/mL) opioid agonist and Schedule III controlled substance with an abuse potential similar to other Schedule III opioids. The high concentration may be a particular target for human abuse. Buprenorphine has opioid properties that in humans may lead to dependence of the morphine type. Abuse of buprenorphine may lead to low or moderate physical dependence or high psychological dependence. The risk of abuse by humans should be considered when storing, administering, and disposing. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (suicidal depression). Because of human safety risks, this drug should be used only with veterinary supervision.

Do not dispense this formulation.

Life-Threatening Respiratory Depression

The concentration of buprenorphine is 1.3 mg/mL. Respiratory depression, including fatal cases, may occur with abuse of this formulation. There are additive CNS depressant effects when used with alcohol, other opioids, or illicit drugs that cause central nervous system depression. Because of the potential for adverse reactions associated with accidental injection, this formulation should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids.

Please see full Ethiqa XR™ Prescribing Information for additional Important Safety Information.